# Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

> **NCT01793883** · PHASE2 · COMPLETED · sponsor: **Biota Scientific Management Pty Ltd** · enrollment: 639 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** 40 mg Laninamivir Octanoate
- **DRUG:** 80 mg Laninamivir Octanoate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01793883
- **Lead sponsor:** Biota Scientific Management Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 639 (ACTUAL)
- **Last updated:** 2018-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01793883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01793883, "Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01793883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*